Ask about this productRelated genes to: SLCO6A1 antibody
- Gene:
- SLCO6A1 NIH gene
- Name:
- solute carrier organic anion transporter family member 6A1
- Previous symbol:
- -
- Synonyms:
- OATP6A1, OATPY, MGC26949, CT48
- Chromosome:
- 5q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-25
- Date modifiied:
- 2016-10-05
Related products to: SLCO6A1 antibody
Related articles to: SLCO6A1 antibody
- Background Breast carcinoma is one of the leading causes of cancer-associated mortality in women worldwide. Although several advances have been made in molecularly classifying breast cancers, treatment resistance continues to limit the overall survival. The Cancer Genome Atlas (TCGA) has unraveled diverse genomic alterations in breast carcinoma. However, some potential biomarkers still remain unexplored, like SETDB1, a histone methyltransferase involved in epigenetic silencing of tumor suppressor genes. ARMCX5 and SLCO6A1 are also some of the unexplored genes that could have a potential role in drug resistance. Materials and methods The Mutation Annotation Format (MAF) data set from the Cancer Genome Atlas Breast Cancer (TCGA-BRCA) cohort was analyzed using the Maftools, Survival, Mclust, and Survminer R packages. Oncodrive driver analysis and protein family (PFAM) domain mapping were performed. A total of 845 cases of breast carcinoma with complete survival data were retrieved, of which mutation data for 800 cases were available. Comprehensive mutation analysis was also done to unveil unexplored genes. Survival data of 845 cases were integrated for Kaplan-Meier and Cox proportional hazard analysis to ascertain the prognostic significance of an array of genes. Oncogenic signaling pathway mapping was done to determine the clinical enrichment of the genes associated with breast carcinoma. Genes associated with clinical enrichment, clustering of somatic mutations, and prognosis were subjected to further analysis. Results Besides the established molecular drivers like PIK3CA and TP53, we found several novel and understudied genes with potential prognostic and oncogenic significance. SETDB1 (p < 0.0001), USP37 (p < 0.0001), NDUFS1 (p = 0.025), TRPM4 (p < 0.0001), and MYO18A (p < 0.0001) were associated with poor prognosis. ARMCX5 (p < 0.0001) and SLCO6A1 (p < 0.0001) were enriched in high-grade tumors. Conclusion The TCGA-BRCA cohort analysis emphasizes a potential interplay of metabolic genes like NDUFS1, TRPM4, ARMCX5, SLCO6A1, and epigenetic axis genes like SETDB1 and USP37 in the oncogenesis and prognosis of breast carcinomas. These observations could open potential avenues for exploring novel therapeutics in aggressive breast carcinomas. - Source: PubMed
Publication date: 2025/12/07
Butta RamanButta Shristi - Purification and preparation of three diagnostic antigens used for the detection of human T-lymphotropic virus (HTLV)-I/-II infection in E.coli are different parts of a multi-step method. In this study, our aim was to design a chimeric protein for the simultaneous detection of HTLV-I and HTLV-II antibodies. Immunodominant B cell linear epitopes of envelope and capsid proteins of HTLV-I/-II were selected and linked together; using a suitable amino acid linker and a chimeric antigen (CA). The codon-optimized synthetic DNA encoding the CA was subcloned into the pGS21aexpression vector and CA expressed as His-GST fused protein in E. coli BL21 (DE3) cells. Then the recombinant CA was purified, using the Ni-NTA (Nickle Nitrilotriacetic acid) affinity chromatography under native conditions. The Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and densitometric scanning results showed that CA accounted for 15% of the total cellular proteins and approximately 50% of the expressed histidine-glutathione s-transferase-chimeric antigen (His-GST-CA) proteins were soluble. The CA was successfully purified in one step with a purity of greater than 90%, which is suitable for antigenicity evaluations. Enzyme-linked immunosorbent assay (ELISA) results showed that the GST fused CA reacted in a concentration-dependent manner with HTLV-I/-II infected sera and was able to distinguish normal serum from HTLV-I/-II infected one with a proper sensitivity. With further validation, CA, as described in the present study could be introduced as a novel reliable, cost-effective and easy alternative for the three separate HTLV-I/-II diagnostic peptide antigens, which is prepared as a fusion with GST. - Source: PubMed
Publication date: 2020/04/16
Bezhgi MahnazFazilati Mohammad - Secondary brain injury imposes great effects on the prognosis of patients following traumatic brain injury (TBI). Accumulating evidence suggests that nuclear factor erythroid 2-related factor 2 (Nrf2) could play a neuroprotective role in experimental TBI models by regulating the expression of numerous antioxidant, anti-inflammatory, and neuroprotective proteins. However, whether Nrf2 is activated in patients following TBI is still unknown. In this study, human brain tissues were obtained during surgery from patients suffering from TBI. The purpose of this study was to investigate the expression of Nrf2 and Nrf2-regulated gene products, NAD(P)H quinine oxidoreductase 1, and glutathione S-transferase in human injured brain tissue after TBI. Our results revealed that the nuclear level of Nrf2 was significantly increased in injured brain tissues, whereas the cytoplasmic level of Nrf2 was markedly decreased. In addition, the expression of NAD(P)H quinine oxidoreductase 1 and glutathione S-transferase was significantly upregulated. Nrf2 may be activated and confer neuroprotection against secondary brain injury following TBI. Therefore, Nrf2 could serve as a promising molecular target for the treatment of TBI. - Source: PubMed
He YuxinYan HuiyingNi HongbinLiang WeibangJin Wei - Our hypothesis was that children with mutations in genes coding for glutathione S-transferases (GST) have worse asthma outcomes compared with children with active type genotype. Data were collected in five populations. The rs1695 single nucleotide polymorphism (GSTP1) was determined in all cohorts (3692 children) and GSTM1 and GSTT1 null genotype were determined in three cohorts (2362 children). GSTT1 null (but not other genotypes) was associated with a minor increased risk for asthma attack and there were no significant associations between GST genotypes and asthma severity. Interactions between GST genotypes and SHS exposure or asthma severity with the study outcomes were nonsignificant. We find no convincing evidence that the GST genotypes studied are related to asthma outcomes. - Source: PubMed
Publication date: 2018/05/22
Turner SteveFrancis BenWani NuhaVijverberg SusannePino-Yanes MariaMukhopadhyay SomnathTavendale RogerPalmer ColinBurchard Esteban GMerid Simon KebedeMelén ErikMaitland-van der Zee Anke HThe Pharmacogenomics In Childhood Asthma Consortium On Behalf Of - A replicative analysis of associations of 15 SNPs located in the regions of 11 genes (TCF4, VRK2, NOTCH4, ZNF804A, AGBL1, RELN, ZFP64P1, KCNB2, CSMD1, CPVL, NRIP1) and three intergenic regions (SLCO6A1/LINCOO491, LOC105376248/LOC105376249, SPA17/NRGN) with schizophrenia was conducted in the Russian population of the Siberian region. These SNPs were previously identified in genome-wide association studies (GWAS) of schizophrenia and cognitive abnormalities. The present study confirmed associations of KCNB2 rs2247572, CSMD1 rs2616984, and intergenic rs12807809 located in SPA17/NRGN with schizophrenia. It was established that the frequency of the CSMD1 rs2616984 G/G genotype was higher in patients compared to the control group (OR = 1.73; CI: 1.14–2.62; р = 0.0337). The frequencies of the KCNB2 rs2247572 TT genotype (OR = 0.41; CI: 0.20–0.87; р = 0.0485) and intergenic rs12807809 CT genotype located in SPA17/NRGN (OR = 0.70; CI: 0.53–0.94; р = 0.0464) were significantly decreased in patients compared to the control group. - Source: PubMed
Bocharova A VStepanov V AMarusin A VKharkov V NVagaitseva K VFedorenko O YuBokhan N ASemke A VIvanova S A